Choong Ang Vaccine Laboratory Co., Ltd. (KOSDAQ:072020)
South Korea · Delayed Price · Currency is KRW 9,760.00
0.00 (0.00%)
At close: Feb 19, 2026
KOSDAQ:072020 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2012 | FY 2011 |
|---|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '12 Dec 31, 2012 | Dec '11 Dec 31, 2011 |
Operating Revenue | 39,190 | 39,299 | 40,914 | 36,318 | 19,263 | 15,589 |
Other Revenue | - | -0 | - | - | - | - |
| 39,190 | 39,299 | 40,914 | 36,318 | 19,263 | 15,589 | |
Revenue Growth (YoY) | -4.18% | -3.95% | 12.66% | 88.53% | 23.57% | -3.15% |
Cost of Revenue | 20,527 | 20,654 | 22,475 | 19,533 | 8,059 | 7,528 |
Gross Profit | 18,663 | 18,645 | 18,439 | 16,784 | 11,204 | 8,062 |
Selling, General & Admin | 11,671 | 11,288 | 11,405 | 10,414 | - | - |
Research & Development | 1,545 | 1,657 | 1,807 | 1,754 | - | - |
Amortization of Goodwill & Intangibles | 122.76 | 120.7 | 175.34 | 211.9 | - | - |
Other Operating Expenses | - | - | - | - | 6,782 | 5,240 |
Operating Expenses | 14,673 | 14,362 | 13,898 | 12,753 | 6,782 | 5,240 |
Operating Income | 3,990 | 4,283 | 4,541 | 4,031 | 4,422 | 2,822 |
Interest Expense | -271.58 | -242.17 | -109.67 | -94.05 | - | - |
Interest & Investment Income | 247.69 | 154.64 | 233.25 | 388.82 | - | - |
Earnings From Equity Investments | 0.12 | - | - | - | - | - |
Currency Exchange Gain (Loss) | 412.08 | 378.86 | 633.49 | -411.58 | - | - |
Other Non Operating Income (Expenses) | 327.26 | 325.94 | 253.21 | 104.85 | 405.41 | 86.07 |
EBT Excluding Unusual Items | 4,706 | 4,900 | 5,552 | 4,019 | 4,828 | 2,908 |
Gain (Loss) on Sale of Investments | -56.83 | -94.09 | 9.93 | 144.69 | - | - |
Gain (Loss) on Sale of Assets | 0.14 | 0.72 | 839.41 | -850.29 | - | - |
Pretax Income | 4,649 | 4,807 | 6,401 | 3,313 | 4,828 | 2,908 |
Income Tax Expense | 1,001 | 762.3 | -1,201 | 149.59 | 455.78 | 540.32 |
Net Income | 3,649 | 4,044 | 7,602 | 3,164 | 4,372 | 2,368 |
Net Income to Common | 3,649 | 4,044 | 7,602 | 3,164 | 4,372 | 2,368 |
Net Income Growth | -55.56% | -46.80% | 140.28% | -27.63% | 84.66% | -48.31% |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 9 | 9 |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 9 | 9 |
Shares Change (YoY) | -0.94% | -0.94% | -0.36% | 12.43% | -0.09% | - |
EPS (Basic) | 375.11 | 414.75 | 772.25 | 320.24 | 497.50 | 269.17 |
EPS (Diluted) | 375.11 | 414.75 | 772.00 | 320.00 | 497.50 | 269.17 |
EPS Growth | -55.12% | -46.27% | 141.25% | -35.68% | 84.83% | - |
Free Cash Flow | 1,387 | -17.84 | -2,785 | -7,088 | -7,269 | 3,180 |
Free Cash Flow Per Share | 142.62 | -1.83 | -282.96 | -717.49 | -827.17 | 361.50 |
Dividend Per Share | 100.000 | 100.000 | - | - | - | - |
Gross Margin | 47.62% | 47.45% | 45.07% | 46.22% | 58.16% | 51.71% |
Operating Margin | 10.18% | 10.90% | 11.10% | 11.10% | 22.96% | 18.10% |
Profit Margin | 9.31% | 10.29% | 18.58% | 8.71% | 22.70% | 15.19% |
Free Cash Flow Margin | 3.54% | -0.04% | -6.81% | -19.52% | -37.73% | 20.40% |
EBITDA | 10,006 | 10,337 | 9,547 | 8,421 | - | - |
EBITDA Margin | 25.53% | 26.30% | 23.34% | 23.19% | - | - |
D&A For EBITDA | 6,016 | 6,054 | 5,006 | 4,390 | - | - |
EBIT | 3,990 | 4,283 | 4,541 | 4,031 | 4,422 | 2,822 |
EBIT Margin | 10.18% | 10.90% | 11.10% | 11.10% | 22.96% | 18.10% |
Effective Tax Rate | 21.52% | 15.86% | - | 4.52% | 9.44% | 18.58% |
Advertising Expenses | - | 423.11 | 478.96 | 376.54 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.